Turkey: Pre-Emptive Declaratory Judgments To Determine Whether Intellectual Property Infringement Exists In Turkey

Many years of intensive research and development activities are required to build solid and commercially profitable intellectual property assets. Companies invest substantial time and resources in technologies, design, research, and development to ultimately produce these intangible assets. Such assets are central to companies maintaining and enhancing their market position. Thus, companies adopt a range of measures to protect these intellectual property assets, including declaratory judgments described below.

Declaratory Judgment Actions to Determine Non-infringement

Obtaining a declaratory judgment in which a court determines that infringement has not occurred ("non-infringement determination") is a key pre-emptive defensive measure for protecting intellectual property. Sector-leading companies invest heavily in developing intellectual property rights. Therefore, it is common for these companies to also become embroiled in patent and trademark litigation wars to protect their investment.

Turkish law allows any interested party to ask the courts for a non-infringement determination against the registered owner of the relevant trademark, patent, or industrial design (the "Right Owner"). The legal framework in Turkey for such actions is outlined separately in the respective legislation relating to trademarks, industrial designs, and patents.

Prior to initiating proceedings, the requesting party will usually send a notice to the Right Owner through a notary public. The notice enables the Right Owner to comment on the requesting party's manufacturing activities, or manufacturing preparations.

The requesting party is entitled to initiate proceedings to obtain a non-infringement determination if either the Right Owner does not respond within one month of receiving the notice, or the requesting party is not satisfied with the Right Owner's response.

It is mandatory to seek the Right Owner's comments in the context of trademarks and industrial designs. Completing this step is a pre-requisite for initiating proceedings to obtain a non-infringement determination. For patents though, parties can directly initiate proceedings seeking non-infringement determinations without first seeking comments from the Right Holder. As a result, patent Right Owners can unexpectedly find themselves as defendants in such actions.

Proceedings seeking a non-infringement determination cannot be initiated against the Right Owner if infringement proceedings have already been initiated with regard to the intellectual property right in question. However, it is possible to initiate proceedings which at the outset jointly claim invalidity, as well as seek a non-infringement determination. When initiating proceedings, all parties noted in the Turkish Patent Institute's registry must be notified.

Non-infringement Determinations to Protect Pharmaceutical Patents

Proceedings seeking non-infringement determinations are particularly important for pharmaceutical patents, which require lengthy and expensive research and development investments. There are two main types of entity in the context of pharmaceutical research and development:

  • Innovator companies which produce original drugs by investing vast amounts of money, time, and resources into development, clinical trials, and manufacturing. Therefore, innovator companies play a significant and influential role in determining market dynamics for the pharmaceutical sector.
  • Generic companies which produce generic alternatives to original drugs. Generic drugs are the equivalent of original drugs in dosage form, safety, strength, quality, and performance. They are chemically identical to their reference counterparts (produced by innovator companies). A generic drug contains the same active substance(s) as the original drug. It should be identical in strength and dosage form to treat/heal the same disease(s), as well as being bioequivalent. However, its appearance and packaging can differ from the original drug.

Since innovator companies invest large amounts of time and money into their development activities, it is reasonable that mechanisms should exist which ensure they can reap the benefits of their efforts and be supported in further innovation activities. On the other hand, initiating proceedings for non-infringement determinations help generic companies to avoid being later required to defend themselves in infringement actions.

Innovator companies tend to prevent generic companies from entering the market with a generic copy of their original drug by patent thickets and follow-on patents. An innovator company may register patents in multiple categories, which are entirely identical to the original patent registration. In this way, the innovator company can refresh the basic patent protection by means of secondary or follow-on patents. These are primarily designed to keep competitors (including generic companies) out of the market.

No pharmaceutical product for human use in Turkey may be marketed unless it is authorized by the Ministry of Health. In granting a marketing authorization, the Ministry requires drug producers to submit the results of their pharmaceutical products' safety and efficacy tests, along with other documents regarding the product. During the data exclusivity period, generic drug producers cannot use or rely on the data gathered by innovator companies to obtain marketing authorization for a generic drug. However, if a patent exists, but no data exclusivity, third parties can apply for a marketing authorization without infringing on the patent (Article 75(f) of the Patent Decree Law). The applicant is not able to actually manufacture the generic drug though, due to the continuing patent protection. However, despite this manufacturing restriction, filing a marketing authorization while the patent is still active will save time.

If neither patent nor data exclusivity protection exist, generic companies are permitted to both manufacture and sell the generic drug in Turkey, provided the company holds marketing authorization.

Therefore, it is possible to create a generic drug without causing patent infringement if:

  • The basic data in the marketing authorization application is not protected by patent or data exclusivity mechanisms;
  • Both the patent and data exclusivity protection has expired.
  • The patent is invalid.

Consequently, generic companies acting defensively may choose to initiate proceedings seeking a non-infringement determination from the court which states that their generic product does not infringe patent rights. Such an action would be initiated after applying for marketing authorization to market and sell the product in Turkey. Under the Turkish Patent Law, generic companies can directly initiate such proceedings without first seeking comments from the related patent Right Holder. Therefore, in Turkey innovator companies can suddenly or unexpectedly be faced with a non-infringement determination action initiated by generic companies.

In case a non-infringement action is initiated against an innovator company since Turkish law requires the data which a marketing authorization application is based on to be kept confidential, irrespective of whether the application relates to an original or generic drug, an innovator company is not permitted to examine the generic applicant's data to determine whether the data infringes on the innovator company's rights. In these circumstances, an innovator company has two possible options:

  • Settlement Negotiations – Any time before or during court proceeding, the innovator company can contact the generic company seeking to find common ground for a possible settlement. During settlement negotiations, the parties may choose to arrange. On the arranged date, the parties would examine the data, in the presence of their lawyers, and an examination date and ask the Ministry of Health for permission to examine the application data without making copies. If the parties agree on the generic product's non-infringing status, a settlement protocol would be prepared and signed.
  • Court Proceedings - The innovator company may prefer to continue with the court proceedings. During proceedings, the court determines an examination date for the parties and/or an appointed expert body. The application data is examined and then an expert report is prepared. The innovator company would submit its opinion and objections regarding the generic drug. Based on these documents, the court makes its determination about whether the generic drug infringes or not.

Declaratory judgment actions are an important tool for innovator and generic companies for protecting their position in the market. Since both types of companies contribute to supporting public health and play an equally important role in the pharmaceutical sector, a careful balance must be maintained between the rights of both of them.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Yonca Çelebi
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.